Table 4.
Variables (N=477) | Survived (n=303) Frequency (%) | Died (n=174) Frequency (%) | χ2 or Fisher’s P Value |
---|---|---|---|
Age, median (IQR) | 50 (39–60) | 60 (47–72) | <.001 |
<18 | 5 (55.6) | 4 (44.4) | <.001 |
18–50 | 146 (76) | 46 (24) | |
>50 | 152 (55.1) | 124 (44.9) | |
Sex (n=476) | |||
Female | 145 (58.7) | 102 (41.3) | .026 |
Male | 157 (68.6) | 72 (31.4) | |
COVID-19 Vaccination Status | |||
Completed | 3 (60) | 2 (40) | .214 |
First dose | 9 (90) | 1 (10) | |
None | 291 (63) | 171 (37) | |
Any comorbidity | 131 (58.7) | 92 (41.3) | .042 |
Hypertension | 80 (56.7) | 61 (43.3) | .046 |
Diabetes mellitus | 54 (58.1) | 39 (41.9) | .223 |
HIV | 17 (54.8) | 14 (45.2) | .299 |
Pregnancy | 6 (75) | 2 (25) | .716 |
COPD | 2 (66.7) | 1 (33.3) | 1.000 |
Malignancies | 2 (100) | 0 (0) | .536 |
Heart failure | 2 (100) | 0 (0) | .536 |
Chronic kidney disease | 1 (50) | 1 (50) | 1.000 |
Presenting complaints | |||
Difficulty in breathing | 235 (60.9) | 151 (39.1) | .014 |
Cough | 244 (64) | 137 (36) | .638 |
Chest pain | 102 (66.2) | 52 (33.8) | .396 |
Fever | 83 (65.9) | 43 (34.1) | .523 |
General body weakness | 64 (66) | 33 (34) | .573 |
Headaches | 26 (76.5) | 8 (23.5) | .104 |
Runny nose | 16 (61.5) | 10 (38.5) | .829 |
Abdominal pain | 12 (92.3) | 1 (7.7) | .038 |
Loss of appetite | 8 (66.7) | 4 (33.3) | 1.000 |
Loss or reduced smell | 7 (63.6) | 4 (36.4) | 1.000 |
Diarrhea | 2 (28.6) | 5 (71.4) | .105 |
Altered mental status | 0 (0) | 4 (100) | .017 |
Vitals at admission | |||
SPO2, median (IQR) | 92 (85–95) | 81 (63–89) | <.001 |
Systolic blood pressure, median (IQR) | 132 (120–145) | 136 (120–149) | .149 |
Diastolic blood pressure, median (IQR) | 81 (71–90) | 78 (69–89) | .169 |
Pulse rate, median (IQR) | 99 (83–110) | 104 (91–116) | .001 |
Respiratory rate, median (IQR) | 25 (20–30) | 32 (28–41) | .000 |
Temperature, median (IQR) | 36.6 (36.1–37.2) | 36.4 (36.2–36.8) | .850 |
Abbreviations: COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus; IQR, interquartile range.